Hawryluk P. Kent 4

What Happened
P. Kent Hawryluk, President & CEO and a director of MBX Biosciences, was granted a total of 199,750 shares of equity compensation on February 2, 2026: 35,250 restricted stock units (RSUs) and a 164,500-share derivative award. Both grants were reported at $0.00 per share (standard for RSU/option awards), so no cash was paid. These are compensation awards (not open-market purchases or sales).

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (timely filing).
• Grants: 35,250 RSUs (reported as acquisition A) and 164,500 derivative shares (reported as acquisition A). Price: $0.00 per share.
• Vesting: RSUs vest over four years in equal quarterly installments (footnote F1). The 164,500-share derivative vests in 48 equal monthly installments beginning March 2, 2026 (footnote F3).
• Shares held via trust: filing notes shares held by the P. Kent Hawryluk Revocable Trust dated Jan 25, 2011; he disclaims beneficial ownership except for any pecuniary interest (footnote F2).
• Shares owned after the transaction: not specified in the supplied filing details.

Context
RSUs and derivative awards are standard executive compensation and only convert into sellable shares as they vest; they do not indicate an immediate purchase or sale by the insider. The grants were reported promptly (next-business-day filing), and the staged vesting ties future ownership to continued service.